|
Market Closed -
Nasdaq
16:00:00 2026-02-13 EST
|
5-day change
|
1st Jan Change
|
|
81.49 USD
|
-0.54%
|
 |
-3.55%
|
-6.70%
|
|
01-28 |
Protagonist Therapeutics Insider Sold Shares Worth $4,063,743, According to a Recent SEC Filing
|
MT
| |
25-10-14 |
Protagonist Therapeutics Insider Sold Shares Worth $979,480, According to a Recent SEC Filing
|
MT
| |
25-07-29 |
Protagonist Therapeutics Insider Sold Shares Worth $570,534, According to a Recent SEC Filing
|
MT
| |
25-07-24 |
Protagonist Therapeutics Insider Sold Shares Worth $2,880,044, According to a Recent SEC Filing
|
MT
| |
25-01-06 |
Protagonist Therapeutics, Inc. Appoints Newman Yeilding as Executive Vice President, Chief Scientific Officer
|
CI
| |
25-01-06 |
Protagonist Therapeutics, Inc. Announces Transition of Suneel Gupta from Chief Development Officer to Executive Vice President, Clinical Development
|
CI
| |
24-11-29 |
Protagonist Therapeutics Insider Sold Shares Worth $5,635,430, According to a Recent SEC Filing
|
MT
| |
24-11-29 |
Protagonist Therapeutics Insider Sold Shares Worth $4,680,749, According to a Recent SEC Filing
|
MT
| |
24-11-29 |
Protagonist Therapeutics Insider Sold Shares Worth $1,414,402, According to a Recent SEC Filing
|
MT
| |
24-09-20 |
Protagonist Therapeutics, Inc. Announces Board Changes
|
CI
| |
24-07-31 |
Protagonist Therapeutics Appoints Newman Yeilding as Chief Scientific Advisor, Effective August 1, 2024
|
CI
| |
24-06-11 |
Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing
|
MT
| |
24-06-11 |
Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing
|
MT
| |
24-04-03 |
Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing
|
MT
| |
24-03-04 |
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing
|
MT
| |
24-03-04 |
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing
|
MT
| |
24-03-04 |
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing
|
MT
| |
23-12-15 |
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing
|
MT
| |
23-10-30 |
Protagonist Therapeutics, Inc. Announces Appointment of Daniel N. Swisher, Jr. to Its Board of Director
|
CI
| |
23-07-03 |
Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director
|
CI
| |
23-01-06 |
Protagonist Therapeutics, Inc. Announces David Liu, Chief R&D Strategy Officer, Transitioned to Part-Time R&D Strategy Advisor
|
CI
| |
22-11-02 |
Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer
|
CI
| |
22-03-28 |
Protagonist Therapeutics Names Asif Ali Finance Chief
|
MT
| |
22-03-23 |
Protagonist Therapeutics, Inc. Announces Resignation of Don Kalkofen as Principal Financial and Accounting Officer
|
CI
| |
21-12-23 |
Insider Sell: Protagonist Therapeutics
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
| 
